Ignite Creation Date:
2024-10-25 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06519981
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-07-02
Brief Title:
Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Dose Escalation Study to Evaluate the Safety Tolerability and Pharmacokinetics of HRS-9231 in Healthy Caucasian Participants
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1 randomized double-blind placebo-controlled study The objective of this study is to evaluate the safety tolerability and PK profile of HRS-9231 injection following a single dose in healthy Caucasian participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None